Watch my explanation
In this short video, I explain why the miR-124 pathway is different from familiar TNF, IL-23, integrin and JAK pathways, and why the maintenance results have made me take this medicine seriously while remaining cautious about longer-term safety.
2026 Update from a UK-trained gastroenterologist in Dubai.
Obefazimod is an investigational once-daily oral medicine that works through a less familiar inflammatory mechanism. This guide explains what miR-124 is, what the Phase 3 maintenance trial reported, the safety questions still being assessed and when an FDA decision might become possible.
Last updated: 23 June 2026